Baricitinib for lung injury after brain bleeding
Treatments studied
Part of Brain & nervous system, Heart & circulation, Infections, Lungs & breathing clinical trials.
This trial tests whether baricitinib, a drug that calms inflammation, can reduce lung injury that often happens after a bleeding stroke in the brain. It is for people admitted to the hospital shortly after the bleed and who have no other major lung or immune conditions.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 18 and 80 years old.
- You must have had a spontaneous (not injury-related) bleed in the space around the brain, confirmed by imaging or a spinal tap.
- Your condition at the hospital must be moderate to severe (graded III or IV on the Hunt-Hess scale).
- You must have arrived at the hospital within 24 hours of your first symptoms.
- You must not have had a lung disease before the bleed (e.g., COPD, bronchiectasis, lung cancer, tuberculosis).
- You cannot have an active infection or fever at the time you are admitted.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests if baricitinib, an anti-inflammatory drug, can help people with bleeding in the brain from a head injury. It is for adults with moderate to severe traumatic brain injury who are not immediately having surgery.
This study tests whether adding the drug baricitinib to standard clot-removal treatment for a certain type of stroke improves recovery. It aims to see if the drug reduces inflammation in the brain and leads to better outcomes.
This trial tests whether baricitinib, a pill that lowers inflammation, can also help reduce blood-clotting risk in people with rheumatoid arthritis. It may help if your arthritis is still active despite current treatment, and you have no other major health conditions.
This trial looks at how a severe brain bleed (subarachnoid hemorrhage) might affect lung function and hyaluronic acid buildup in the lungs. It aims to find better ways to protect breathing for patients in the intensive care unit.
This trial tests whether adding a drug called baricitinib to your usual TPO-RA treatment works better than TPO-RA alone for people with ITP who haven't responded enough to TPO-RA. It aims to see if the combination helps raise platelet counts and reduce bleeding risk.
This trial tests whether a medication called baricitinib can help patients whose platelet counts remain dangerously low after a bone marrow transplant, even after standard treatments. Platelets are blood cells that help stop bleeding, and this study aims to see if baricitinib can restore them.
Hear when a new Spontaneous Subarachnoid Hemorrhage trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.